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Personalized medicinePersonalized medicine is to deliver the right drug to the right patient in the right dose. Pharmacogenom-
ics (PGx) is to identify genetic variants that may affect drug efﬁcacy and toxicity. The availability of a
comprehensive and accurate PGx-speciﬁc drug–gene relationship knowledge base is important for per-
sonalized medicine. However, building a large-scale PGx-speciﬁc drug–gene knowledge base is a difﬁcult
task. In this study, we developed a bootstrapping, semi-supervised learning approach to iteratively
extract and rank drug–gene pairs according to their relevance to drug pharmacogenomics. Starting with
a single PGx-speciﬁc seed pair and 20 million MEDLINE abstracts, the extraction algorithm achieved a
precision of 0.219, recall of 0.368 and F1 of 0.274 after two iterations, a signiﬁcant improvement over
the results of using non-PGx-speciﬁc seeds (precision: 0.011, recall: 0.018, and F1: 0.014) or co-occur-
rence (precision: 0.015, recall: 1.000, and F1: 0.030). After the extraction step, the ranking algorithm fur-
ther improved the precision from 0.219 to 0.561 for top ranked pairs. By comparing to a dictionary-based
approach with PGx-speciﬁc gene lexicon as input, we showed that the bootstrapping approach has better
performance in terms of both precision and F1 (precision: 0.251 vs. 0.152, recall: 0.396 vs. 0.856 and F1:
0.292 vs. 0.254). By integrative analysis using a large drug adverse event database, we have shown that
the extracted drug–gene pairs strongly correlate with drug adverse events. In conclusion, we developed a
novel semi-supervised bootstrapping approach for effective PGx-speciﬁc drug–gene pair extraction from
large number of MEDLINE articles with minimal human input.
 2013 Elsevier Inc. All rights reserved.1. Background
1.1. Pharmacogenomics and personalized medicine
Pharmacogenomics (PGx) is important for personalized medi-
cine. Different patients respond differently to the same drug, with
genetics accounting for 20–95% of the variability [1]. Pharmacoge-
nomics is the study of how human genetic variations affect an indi-
vidual’s response to drugs, with foci on drug metabolism,
absorption, and distribution [2]. Pharmacogenomics plays an
important role in identifying drug responders and non-responders,
avoiding adverse events, and optimizing drug dose [3,4]. Recently,
the U.S. Food and Drug Administration (FDA) has become a strong
pharmacogenomics advocate in an effort to make drugs safer and
more effective [5,6]. In order to improve the quality of already-
marketed drugs, the FDA has updated certain drug labels to include
PGx information. Currently, over one hundred FDA-approved drugs
have PGx information on their labels that describe genes responsi-
ble for drug exposure, clinical response variability, and risk for ad-verse events.1 One of the well-known PGx-speciﬁc drug–gene
associations is warfarin-CYP2C9. Gene CYP2C9 encodes an important
cytochrome P450 (CYP) enzyme that plays a major role in the metab-
olizing of more than 100 therapeutic drugs, one of which is warfarin.
The genetic polymorphisms of CYP2C9 are associated with altered
enzyme activity leading to toxicity at normal therapeutic doses of
warfarin. Understanding how the genetic variants contribute to var-
ious drug responses is an essential step of personalized medicine
[1,7,8]. The success of personalized drug treatment largely depends
on the availability of accurate and comprehensive knowledge bases
of PGx-speciﬁc drug–gene relationships, such as warfarin-CYP2C9
and irinotecan-UGT1A.
1.2. Automatic methods in extracting PGx-speciﬁc drug–gene pairs
from literature
There are substantial research efforts in constructing PGx
knowledge bases using both manual and automatic approaches.
The Pharmacogenomics Knowledge Base (PharmGKB) is the largestgenetics/
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man genetics lead to variations in drug response (http://
www.pharmgkb.org) [9]. The PharmGKB project involves a large
number of curators who read the literature and manually extract
relationships among genes, drugs, and diseases from the pharma-
cogenetic literature. However, manually extracting PGx knowledge
and other biomedical information in general from published liter-
ature and transforming it into machine-understandable knowledge
is a difﬁcult task because biomedical knowledge and terminology
comprise huge, dynamic, and highly complicated ﬁelds. In addi-
tion, human curators are liable to error and subjective bias.
Development of automatic approaches to extract PGx-speciﬁc
drug–gene relationships from published biomedical literature is
an active research area. Both statistical and natural language pro-
cessing (NLP) methods have been used [10–17]. Recently, we have
developed a conditional approach to extract PGx-speciﬁc drug–
gene pairs from 20 million MEDLINE abstracts using known
drug–gene pairs available in PharmGKB as prior knowledge to
implicitly classify sentences before relationship extraction. We
have demonstrated that the conditional drug–gene relationship
extraction approach signiﬁcantly improves the precision and the
F1 measure when compared with the unconditioned approach
[18]. One common feature among above studies is that these
drug–gene relationship extraction algorithms used either PGx-spe-
ciﬁc gene lexicons as input or PGx-related articles as the text cor-
pus. These gene lexicons were either manually compiled or were
derived from PharmGKB drug–gene pairs. PharmGKB is the largest
pharmacogenomics knowledge, however the genes in this knowl-
edge are often a mixture of non PGx-speciﬁc genes (e.g., IL2,
VDR, EGFR, KRAS, ERBB2, and BRCA1) and PGx-speciﬁc genes
(CYP2C9, VKORC1, ABCB1, UGT1A). Correspondingly, the drug–
gene pairs in PharmGKB are also a mixture of non PGX-speciﬁc
pairs. In addition, the recall of the PharmGKB gene lexicon is also
limited. For example, there are total of 60 CYP (cytochrome
P450) gene symbols approved by the HUGO Gene Nomenclature
Committee (HGNC) (http://www.genenames.org/), but PharmGKB
contains only 30 of them. Therefore, in order to increase the recall
of extracted drug–gene pairs, we need to either compile a more
comprehensive PGx-speciﬁc gene lexicon as done in [19], or start
from all human genes and develop an algorithm to extract valid
drug–gene pairs and classify them by their PGx-relevance.
1.3. Our semi-supervised iterative approach in extracting PGx-speciﬁc
drug–gene pairs from literature
In this study, instead of using a precompiled PGx-speciﬁc gene
lexicon, we use all human protein coding genes (total 19,055) as
the underlying gene lexicon input to the drug–gene extraction
algorithm. Since PGx-speciﬁc drug–gene pairs only account for a
very small of portion of all drug–gene semantic pairs, using all hu-
man genes as the input gene lexicon makes the task of extracting
PGx-speciﬁc drug–gene pairs more challenging and interesting.
Therefore, it is critical to develop a ranking algorithm to rank ex-
tracted drug–gene pairs according to their PGx relevance. Another
critical difference from our previous knowledge-driven approach
[18] is that instead of using a signiﬁcant portion of PharmGKB
drug–gene pairs as prior knowledge, we use only one or a few
known PGx-speciﬁc drug–gene pairs (e.g. warfarin-CYP2C9, or caf-
feine-CYP1A2) as seeds to start the whole extraction process. Our
previous conditional approach was guided by many known drug–
gene pairs and therefore constituted a supervised learning ap-
proach. The method we present in this study is a semi-supervised
approach since it depends on only a few seeds to start the whole
learning process. Our study is based on the assumption that PGx-
speciﬁc drug–gene pairs are often clustered together in a sentence.
If we start with a known PGx-speciﬁc pair such as warfarin-CYP2C9, it is likely that sentences containing this pair are also
PGx-speciﬁc. The other drug–gene pairs extracted from these
PGx-related sentences are likely PGx-speciﬁc. The likelihood in-
creases as the relatedness of the sentences increases, which de-
pends on the relatedness of other drug–gene pairs in it. For
example, using seed pair ‘‘warfarin-CYP2C9’’, we retrieved the fol-
lowing sentence ‘‘Genetic factors (VKORC1, CYP2C9, EPHX1, and
CYP4F2) are predictor variables for warfarin response in very el-
derly, frail inpatients.’’ (PMID19794411). Since this sentence con-
tains a PGx-speciﬁc drug–gene pair warfarin-CYP2C9, the
sentence itself is highly likely to be related to PGx. The other three
drug–gene pairs (warfarin-VKORC1, warfarin-EPHX1, and warfain-
CYP4F2) are likely to be PGx-speciﬁc pairs.
Recent studies in semi-supervised iterative learning approaches
are motivated by the use of a very large collection of texts (web)
[20] and the possibility of handling multiple entity types [21].
Semi-supervised pattern learning approaches are advantageous
because they require minimal human intervention and no external
domain knowledge. Therefore, semi-supervised information
extraction systems are able to extract broad types of entities and
relationships. Semi-supervised learning approaches have been
used to extract information from the web [22–29]. Semi-super-
vised learning approaches depend on the regularity of language
and the data redundancy. A big corpus such as MEDLINE (22 mil-
lion articles as of the year 2012) is ideal for such tasks. However,
the potential for semi-supervised approaches for biomedical infor-
mation extraction was not fully explored until recently, when we
developed semi-supervised pattern learning approaches for dis-
ease entity recognition [30] and medical intervention entity recog-
nition [31], isa relationship extraction [32], and medical image
retrieval from the web [33]. All iterative learning systems suffer
from the inevitable problem of spurious patterns and instances
introduced in the iterative process. We develop an iterative rank-
ing algorithm to rank extracted drug–gene pairs according to their
PGx-relatedness by combining the frequency of drug–gene pairs in
MEDLINE with the PGx speciﬁcity of other co-occurred drug–gene
pairs. The ranking algorithm is similar to the topic sensitive Page-
Rank algorithm developed by Haveliwala [34]. Topic-Sensitive
PageRank was based on the PageRank algorithm [35] in order to
personalize search rankings using link analysis. Topic-sensitive
PageRank computed a set of PageRank vectors, biased using a set
of representative topics, in order to capture the importance with
respect to a particular topic (details in Section 2).2. Data and methods
Fig. 1 depicts the iterative process of PGx-speciﬁc drug–gene
extraction. The system consists of the following components: (1)
build a local MEDLINE search engine; (2) iteratively extract
drug–gene pairs; (3) rank extracted pairs; and (4) analyze ex-
tracted pairs.2.1. Build local MEDLINE search engine
We have used 20 million MEDLINE abstracts (roughly 100 mil-
lion sentences) published from 1965 to 2010 as the text corpus for
our task of PGx-speciﬁc drug–gene relationship extraction. The
2010 MEDLINE/PubMed baseline XML ﬁles were downloaded from
NLM’s anonymous FTP server at ftp://ftp.nlm.nih.gov/nlmdata/
.medleasebaseline/. The MEDLINE XML ﬁles were then parsed.
The abstracts and PMID information from the XML ﬁles were ex-
tracted. Abstracts were subsequently split into sentences. We used
the publicly available information retrieval library Lucene (http://
lucene.apache.org) to create a local search engine with
indexes for both sentences and abstracts. The drug lexicon was
Fig. 1. System diagram of iterative drug–gene extraction, pair ranking and semantic analysis process.
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2012, and contains 6516 drugs. The gene symbols were down-
loaded from www.genenames.org in 05/2012 and consisted of
19,055 human protein coding gene symbols.
2.2. Extract drug–gene pairs
The iterative process starts with a typical PGx-speciﬁc drug–
gene seed pair such as ‘‘warfain-CYP2C9’’ or ‘‘caffeine-CYP1A2.’’
The program loops over a procedure that consists of a sentence
extraction step and a pair extraction step (Fig. 1). In the sentence
extraction step, the seed pair(s) are used as search queries to the
local search engine. The sentences or abstracts containing the
seed(s) are retrieved. In the pair extraction stage, we ﬁrst ﬁnd
gene and drug entities from these returned sentences, and then
extract the drug–gene co-occurrence pairs from the sentences.
We use case-insensitive exact string matching for drug entity
tagging, and case-sensitive extract string matching for gene sym-
bol tagging. In the sentence extraction step in the subsequent
iteration, the drug–gene pairs extracted from the previous itera-
tion are used as queries to retrieve more sentences from which
more drug–gene pairs are extracted. After each iteration, we
rank the extracted drug–gene pairs and evaluate the precision
and recall. The process was stopped after three iterations since
further iterations did not improve the recall while precision
decreased.
2.3. Rank drug–gene pairs
The ranking score of drug–gene pairs according to their PGx-
speciﬁcity at a given iteration is given as the following:
RSðPiNÞ ¼
Xk
j¼0
ðWijRSðPijN1ÞÞ
The term on the left is the ranking score of a drug–gene pair being
PGx-speciﬁc in iteration N, and the term within the summation on
the right is the ranking score of its co-occurring drug–gene pairs
(Pij) being PGx-speciﬁc in iteration N-1, weighted by co-occurrence
frequency (Wij). K is the number of co-occurrence drug–gene pairs
for pair Pi. Starting from a seed drug–gene pair, the ranking algo-
rithm iteratively propagates its conﬁdence score to its co-occurred
pairs. The ranking score of each drug–gene pair is the sum of scores
of its co-occurring pairs weighted by co-occurrence count. The con-
ﬁdence score of the seed pair was given a score of 1.0. For example,
starting with the seed pair warfarin-CYP2C9, we extracted four
additional genes P1, P2, P3 and P4 after ﬁrst iteration, with the
co-occurrence (with seed) counts 100, 20, 10, and 1, respectively.
Then the weight of P1 after the ﬁrst iteration is (100/131)  1.0. At
the second iteration, the ranking scores are calculated again basedon the score vector from the ﬁrst iteration. If more than one seed
has been used, the initial scores of these seeds is one divided by
the number of seeds. In one of our experiments in investigating
the effect of number of seeds on the whole drug–gene extraction
and ranking process, we used 68 drug–gene pairs extracted from
FDA drug labels. The initial score for each of these 68 seeds was
1/68. The basic idea of our ranking algorithm is that if a sentence
or abstract contains a known PGx-speciﬁc seed drug–gene pair,
then the topic (or classiﬁcation) of this sentence is related to PGx
study. Other drug–gene pairs contained in the sentence are likely
PGx-speciﬁc. The degree of PGx speciﬁcity a sentence confers to
the unknown drug–gene pairs in it depends on the scores of the
known drug–gene pairs in the same sentence. The difference from
Topic Sensitive PageRank algorithm is that instead of continue the
iteration process until rank stabilizes to within some threshold,
we evaluate the performance at each iteration and stop the iteration
process after certain iterations.2.4. Evaluation
We used the drug–gene pairs from PharmGKB as the gold stan-
dard. As we discussed previously, the drug–gene pairs in PhamGKB
are limited in both precision and recall. However, as long as the
drug–gene pairs in PharmGKB are largely PGx-speciﬁc and not
biased to certain sets of drugs or genes, using them as gold stan-
dard to compare different algorithms should give fair evaluation.
We downloaded the PharmGKB databases in 04/2012. There are
a total of 4399 drug–gene pairs classiﬁed as ‘‘PD’’ (pharmacody-
namics) and/or ‘‘PK’’ (pharmacokinetics). Among them, 1561 pairs
appeared in MEDLINE sentences and 2083 in MEDLINE abstracts.
We used the 1561 pairs appearing in MEDLINE sentences as the
gold standard for sentence-level drug–gene extraction evaluation.
Similarly, we used the 2083 pairs appearing in MEDLINE abstracts
as the gold standard for abstract-level extraction evaluation. Preci-
sion, recall and F1 measures were used for both relationship
extraction and ranking. Precision was calculated as the proportion
of gold standard pairs amongst extracted and ranked pairs. The re-
call was estimated as the proportion of all gold standard pairs ex-
tracted. The F1 measure was deﬁned as the harmonic mean of
precision and recall: F1 = 2  (precision  recall)/(precision + recall).
One tailed Z statistics for two proportions was used to test
signiﬁcance.2.5. Analyze drug–gene pairs
Studies have shown that PGx-speciﬁc genes are responsible for
drug toxicities [36]. To demonstrate the potential use of the ex-
tracted PGx-speciﬁc drug–gene pairs in drug adverse event predic-
tion, we studied the correlations of these extracted drug–gene
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drug adverse event pairs from SIDER (Side Effect Resource), a side
effect resource compiled from FDA package inserts using text-min-
ing methods [37] (http://sideeffects.embl.de/download/, accessed
03/2012). These drug adverse event pairs contained 996 drugs.
For drug–drug pairs that shared PGx-speciﬁc genes bases on the
extracted drug–gene pairs, we calculated the average shared ad-
verse events and compared them to that shared among all drug–
drug pairs.3. Results
3.1. Performance comparison of the extraction algorithms based on
different types of seeds
We compared the performances of different types of drug–gene
seeds on the overall drug–gene extraction algorithm. The seeds in-
cluded PGx-speciﬁc drug–gene pairs (Warfarin-CYP2C9 or Caf-
feine-CYP1A2) and a non-PGx-speciﬁc pair (Captopril-ACE). We
also compared the extraction algorithm using seed pairs to the
one without using any seeds. We investigated the effects of the
number of iterations (one, two, and three iterations) and document
types (sentence-level vs. abstract level) on the overall extraction
algorithm. As shown in Table 1, the drug–gene extractions using
PGx-speciﬁc seeds (‘‘Warfarin-CYP2C9’’ or ‘‘Caffeine-CYP1A2’’)
had signiﬁcantly better precision, recall, and F1 values compared
to those using the non-PGx-speciﬁc seed (‘‘Captopril-ACE’’) or pure
co-occurrence (‘‘None’’). After two iterations, the algorithm ex-
tracted a total of 2622 drug–gene pairs starting from the seed war-
farin-CYP2C9, with a precision of 0.219, a recall of 0.368, and an F1
of 0.274 (Z score = 66.17 and p-value = 0). Similarly, starting with
the seed caffeine-CYP1A2, the algorithm extracted a total of 2578
drug–gene pairs, with a precision of 0.195, a recall of 0.322, and
an F1 of 0.243 (Z score = 57,90 and p-value = 0). The overall preci-
sion and recall for these two PGx-speciﬁc seeds are similar. How-
ever, if a non-PGx-speciﬁc seed (‘‘Captopril-ACE’’) or no seed
(‘‘NONE’’) was used, the performance measures were at least tenTable 1
Comparison of drug–gene extraction using different types of seeds: PGx-speciﬁc seeds (‘‘W
no seeds (‘‘None’’).
Document type Round Seed
Sentence 1 Warfarin-CYP2C9
2
3
1 Caffeine-CYP1A2
2
3
1 Captopril-ACE
2
3
Co-occurrence None
Abstract 1 Warfarin-CYP2C9
2
3
1 Caffeine-CYP1A2
2
3
1 Captopril-ACE
2
3
Co-occurrence None
a (Z score = 66.17 and p-value = 0)
b (Z score = 57,90 and p-value = 0)
c (Z = -4.7, p = 0)
d (Z = 78.8, p = 0)
e (Z = 77.8, p =0)
f (Z = 4.5, p = 0)times lower (precision of 0.011, recall of 0.018, and F1 of 0.014
for ‘‘Captopril-ACE’’, precision of 0.015, recall of 0.134, and F1 of
0.026 for ‘‘None’’). Similar results were observed for the other
non-PGx-speciﬁc seed ‘‘Geﬁtinib-EGFR’’ (data not shown). After
one iteration, we extracted a total of 391 drug–gene pairs from
sentences starting from seed warfarin-CYP2C9, with a precision
of 0.340, a recall of 0.085, and an F1 of 0.136. After two iterations,
the algorithm extracted 2622 pairs, with lower precision (0.219)
but higher recall (0.368) and F1 (0.274). As we ran the algorithm
for another iteration (three iterations), the recall increased as ex-
pected, but both precision and F1 signiﬁcantly decreased. The same
trend was observed for the seed ‘‘Caffeine-CYP1A2.’’ By comparing
sentence-level to abstract-level drug–gene relationship extrac-
tions, we have shown that sentence-level extraction in general
had better precision and F1 value, but lower recall. For instance,
the drug–gene pairs extracted from sentences after two iterations
had a precision of 0.219, a recall of 0.368, and an F1 of 0.274. The
ones extracted from abstracts had a lower precision of 0.085, a
higher recall of 0.511, and a lower F1 of 0.145.
In summary, more than half of the PGx-speciﬁc drug–gene pairs
were reachable from a PGx-speciﬁc seed in only three hops as
shown by the greater than 0.5 recall values after three iterations.
Starting from a non-PGx-speciﬁc seed, only around 13% (recall of
0.134) of all PGx-speciﬁc drug–genes proved reachable after three
iterations. This demonstrated that PGx-speciﬁc drug–gene pairs
are indeed clustered together in sentences or abstracts. Compared
to drug–gene pairs extracted based on co-occurrence, the pairs ex-
tracted using PGx-speciﬁc seeds were highly enriched in PGx-spe-
ciﬁc pairs.3.2. Performance of extraction algorithm using different number of
PGx-speciﬁc seeds
As we have shown in previous section, the drug–gene pairs ex-
tracted starting from one PGx-speciﬁc seed were signiﬁcantly en-
riched with PGx-speciﬁc pairs (precision 0.219) compared to
those extracted using a non-PGx-speciﬁc seed or based on purearfarin-CYP2C9’’ and ‘‘Caffeine-CYP1A2’’), non PGx-speciﬁc seed (‘‘Captopril-ACE’’) and
N Precision Recall F1
391 0.340 0.085 0.136
2622 0.219 0.368 0.274a
8844 0.103 0.583 0.175
397 0.270 0.069 0.109
2578 0.195 0.322 0.243b
8534 0.097 0.529 0.164
319 0.053 0.011 0.018
2545 0.011 0.018 0.014c
14,278 0.015 0.134 0.026
102,916 0.015 1.000 0.030
1262 0.222 0.134 0.167
12,580 0.085 0.511 0.145d
68,415 0.025 0.823 0.049
1028 0.198 0.098 0.131
10,793 0.09 0.467 0.151e
69,653 0.025 0.796 0.049
897 0.025 0.011 0.015
20,106 0.015 0.144 0.027f
96,086 0.016 0.749 0.032
190,452 0.011 1.000 0.022
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gated whether or not we could improve both precision and recall
by starting with more PGx-speciﬁc seeds. We experimented with
the extraction algorithm starting with one seed (‘‘Warfarin-
CYP2C9’’ or ‘‘Caffeine-CYP1A2’’), two seeds ((‘‘Warfarin-CYP2C9’’
and ‘‘Caffeine-CYP1A2’’), and 68 PGx-speciﬁc drug–gene pairs ex-
tracted from FDA drug labels. As shown in Table 2, there was a
tradeoff in precision and recalls caused by using a different number
of seeds. After two iterations, the algorithms with 68 seeds had sig-
niﬁcant better recall compared to that which had one seed (0.522
vs. 0.368); however the precision decreased from 0.219 to 0.171.
The overall F1 values were similar among algorithms using one
seed, two seeds, and 68 seeds. After three iterations, we had ex-
tracted the majority of the PGx-speciﬁc drug–gene pairs when 68
seeds were used (recall of 0.701 for sentence-level and, 0.876 for
abstract-level); however the overall precision was low.
In summary, the extraction algorithm is effective in ﬁnding
PGx-speciﬁc drug–gene pairs. However, the low precision demon-
strated the need to develop a ranking algorithm to further rank
PGx-speciﬁc pairs highly amongst the extracted pairs.
3.3. Performance comparison of different ranking algorithms
We developed three ranking methods to rank the extracted
drug–gene pairs: (1) ranking based on the scores calculated using
the formula deﬁned in Section 2; (2) ranking based on MEDLINE
frequency count. The intuition behind the MEDLINE frequency-
based ranking is that if a drug–gene pair co-occurs in MEDLINE
many times, it is likely that there is some semantic relationship be-
tween the drug and the gene; (3) random ranking. We used the 11-
point interpolated average precision measures, often used for mea-
suring ranked retrieval results for search engines [38], to evaluate
the drug–gene ranking algorithms. The interpolated precision was
measured at the 11 recall levels of 0.0,0.1,0.2, . . . ,1.0. The interpo-
lated precision pinterp at 11 recall cutoff values r is deﬁned as the
highest precision found for any recall value r0 P r:
PinterpðrÞ ¼ max
r0Pr
pðr0ÞTable 2
Comparison of drug–gene extraction using different number of seeds: none, one, two, and
Document type Round Seed
Sentence 1 Warfarin-CYP2C9
2
3
1 Warfarin-CYP2C9 + Caffeine-CYP
2
3
1 68 FDA drug–gene pairs
2
3
Co-occurrence None
Abstract 1 Warfarin-CYP2C9
2
3
1 Warfarin-CYP2C9 + Caffeine-CYP
2
3
1 68 FDA drug–gene pairs
2
3
Co-occurrence None
a (Z = 66.1, p = 0)
b (Z = 66.4, p = 0)
c (Z = 78.4, p = 0)
d (Z = 78.8, p = 0)
e (Z = 76.3, p = 0)
f (Z = 71.4, p = 0)The precision-recall curves for both sentence- and abstract-le-
vel extractions after two iterations are shown in Fig. 2. The preci-
sion-recall curves after three iterations are shown in Fig. 3. In
each of these ﬁgures, we plotted the precision-recall curves for
pairs ranked by pure MEDLINE frequency (‘‘Cooc_All’’), by method
1 (‘‘Warfarin_CYP2C9_ranked’’ and ‘‘FDA_PGx_ranked’’), and for
random ranking (‘‘Warfarin_CYP2C9_random’’ and ‘‘FDA_PGx_ran-
dom’’). As shown in the ﬁgures, the precision for both random
ranking and ranking by MEDLINE frequency were low at all cutoff
recall values. On the other hand, the ranking algorithm we devel-
oped was able to rank PGx-speciﬁc drug–gene pairs highly
amongst extracted pairs. For instance, the precision at recall of
0.10 was 0.881 for ‘‘Warfarin_CYP2C9_ranked’’, compared to 0.26
for ‘‘Cooc_All’’ and 0.357 for ‘‘Warfarin_CYP2C9_random’’ (Fig. 2).
Similar trends were seen for both sentence-level and abstract-level
extraction after two or three iterations. This demonstrated that our
ranking algorithm was robust and insensitive to the seeds used
(warfarin-CYP2C9 vs. FDA PGx seeds), number of seeds used (one
seed vs. 68 seeds), iterations (two or three iterations), or document
types (sentences vs. abstracts).3.4. Ranked precision, recall and F1
We have demonstrated that starting from a few PGx-speciﬁc
seeds, our extraction algorithm is able to effectively extract many
other PGx-speciﬁc drug–gene pairs from either MEDLINE sen-
tences or abstracts. We have also shown that the ranking algorithm
is able to further rank PGx-speciﬁc drug–gene pairs highly among
extracted pairs. Table 3 is the summary of precision, recall, and F1
at different ranking cutoffs for both PGx-speciﬁc and non-speciﬁc
seeds. After two iterations, we extracted a total of 2622 pairs with
precision of 0.219, recall of 0.368, and F1 of 0.323. After ranking,
the top 50% of ranked pairs had improved precision of 0.354 and
F1 of 0.323 with decreased recall. The ranked F1 measures for War-
farin-CYP2C9 and 68 FDA drug–gene pairs are similar at all cutoffs.
The pairs extracted with non-PGx-speciﬁc seed (‘‘Captopril-ACE’’)
or based on pure co-occurrence without seeds (‘‘None’’) had signif-
icantly lower precision and F1 at all cutoffs.68 PGx-speciﬁc seeds.
N Precision Recall F1
391 0.340 0.085 0.136
2622 0.219 0.368 0.274a
8844 0.103 0.583 0.175
1A2 669 0.281 0.120 0.169
3146 0.192 0.386 0.256b
10,811 0.087 0.603 0.152
1524 0.278 0.272 0.275
4767 0.171 0.522 0.258c
15,798 0.069 0.701 0.126
102,916 0.015 1.000 0.030
1262 0.222 0.134 0.167
12,580 0.085 0.511 0.145d
68,415 0.025 0.823 0.049
1A2 1879 0.185 0.167 0.175
15,434 0.075 0.554 0.132e
77,344 0.023 0.836 0.044
3886 0.165 0.308 0.215
26,089 0.057 0.711 0.105f
99,376 0.018 0.876 0.036
190,452 0.011 1.000 0.022
Fig. 2. Ranked precision after two iterations for sentence-level (left) and abstract-level (right) drug–gene pair extraction.
Fig. 3. Ranked precision after three iterations for sentence-level (left) and abstract-level (right) drug–gene pair extraction.
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gene pairs from MEDLINE sentences
A total of 4399 PGx-speciﬁc (with subtype ‘‘PD’’ or ‘‘PK’’) drug–
gene pairs were extracted in PharmGKB and consist of 637 drugs
and 859 genes. We used the 859 genes and the 637 drugs as the
inputs to a dictionary-based PGx-speciﬁc drug–gene extraction
algorithm. Since both of these genes and drugs are from PGx-spe-
ciﬁc drug–gene pairs, we assume that they are more PGx-speciﬁc
than those not contained in PharmGKB. On the other hand, the
bootstrapping approach used all 19,055 human protein coding
genes and 6516 drugs from DrugBank as inputs. We compared
the dictionary-based approach to the bootstrapping approach
(with seed ‘‘Warfarin-CYP2C9’’ or 68 FDA drug–gene pairs) in
terms of precision, recall and F1. Among the 4399 pairs from Phar-
mGKB, 1561 pairs co-occurred in MEDLINE sentences. We used
these 1561 pairs as goldstandard for both approaches in extracting
drug–gene pairs from MEDLINE sentences. In fact, this evaluation
dataset favors the dictionary-based approach towards high recall
(recall of 1.0). It will underestimate precision of the bootstrappingapproach when it extracts PGx-speciﬁc pairs that are not included
in the goldstandard dataset. Using the dictionary-based approach,
we extracted a total of 12,444 co-occurrence pairs from sentences.
We then ranked the extracted pairs according to their co-occur-
rence frequency. We measured the precision, recall and F1 at two
ranking cutoffs: top 50% and top 100% (all) pairs. As shown in
Table 4, the dictionary-based approach achieved a precision of
0.178, a recall of 0.711 and a F1 of 0.285 at cutoff of 50%, and a pre-
cision of 0.125, a recall of 1.000 and a F1 of 0.223 at cutoff of 100%.
It seems that ranking by co-occurrence frequencies can improve
the precision. Compared to the dictionary-based approach, the
bootstrapping approach has signiﬁcantly higher precisions at all
corresponding cutoffs: average precision of 0.152 for the dictio-
nary-based approach vs. average precision of 0.251 for the boot-
strapping approach. The recall of the dictionary approach
(average of 0.856) is signiﬁcantly higher than that of the bootstrap-
ping approach (average of 0.396) partly because of the speciﬁc
evaluation dataset we used. We used drug–gene pairs (with sub-
type ‘‘PD’’ or ‘‘PK’’) from PharmGKB as evaluation set. Even though
PharmGKB is a manually curated knowledge base, we found out
Table 3
Summary of ranked precision, recall and F1.
Seed Cutoff (%) N Precision Recall F1
Warfarin-CYP2C9 10 262 0.561 0.094 0.161
25 655 0.472 0.198 0.279
50 1311 0.354 0.297 0.323a
75 1966 0.273 0.343 0.304
100 2622 0.219 0.368 0.274b
68 FDA drug–gene pairs 10 476 0.374 0.114 0.175
25 1191 0.335 0.256 0.290
50 2383 0.260 0.397 0.314c
75 3575 0.209 0.479 0.291
100 4767 0.171 0.522 0.258d
Captopril-ACE 10 254 0.063 0.010 0.018
25 636 0.033 0.013 0.019
50 1272 0.019 0.015 0.017e
75 1908 0.013 0.016 0.014
100 2545 0.011 0.018 0.014f
None 10 10,291 0.054 0.359 0.094
25 25,729 0.035 0.575 0.066
50 51,458 0.024 0.783 0.046
75 77,187 0.018 0.896 0.036
100 102,916 0.015 1.000 0.030
a (Z = 58.4, p = 0)
b (Z = 66.1, p = 0)
c (Z = 73.1, p = 0)
d (Z = 78.4, p = 0)
e (Z = -2.7, p = 0.003)
f (Z = -4.7, p = 0)
Table 4
Comparison of bootstrapping approach with the dictionary-based approach with drugs and genes from PharmGKB PGx-speciﬁc drug–gene pairs as input.
Method Cutoff (%) N Precision Recall F1
Bootstrapping (Seed ‘‘Warfarin-CYP2C9’’) 50 1311 0.354 0.297 0.323
100 2622 0.219 0.368 0.274
Bootstrapping (Seeds 68 FDA drug–gene pairs) 50 2383 0.260 0.397 0.314
100 4767 0.171 0.522 0.258
Dictionary-based Approach 50 6222 0.178 0.711 0.285a
100 12,444 0.125 1.000 0.223b
None (co-occurrence with 19,055 genes and 6516 drugs) 50 51,458 0.024 0.783 0.046
100 102,916 0.015 1.000 0.030
a (Z = -2.7, p = 0.003, which is signiﬁcantly lower when compared to the F1 score of 0.323 at cutoff 50% for Bootstrapping with seed ‘‘Warfarin-CYP2C9)
b (Z = -5.6, p = 0, which is signiﬁcantly lower when compared to the F1 score of 0.274 at cutoff 100% for Bootstrapping with seed ‘‘Warfarin-CYP2C9)
R. Xu, Q. Wang / Journal of Biomedical Informatics 46 (2013) 585–593 591that some drug–gene pairs in PharmGKB are non-PGx-speciﬁc pairs,
such as cetuximab-EGFR, cisplatin-EGFR, caffeine-BRCA1, cisplatin-
BRCA1, alendronate-VDR, and pioglitazone-IL6. In fact, by a quick
search using term ‘IL’, we found that a total of 34 drug–gene pairs
(with assigned subtype ‘PD’ or ‘PK’) are associated with interleukin
ligandor receptor genes suchasgeﬁtinib-IL15, geﬁtinib-IL8, andgef-
itinib-IL8RA. Inclusion of these non-PGx-speciﬁc drug–gene pairs in
the evaluation set will decrease the recall of the bootstrapping
method since itmaynot retrieve these non-PGx-speciﬁc pairs. How-
ever, the average F1 of the dictionary-based approach is 0.254,
which is lower than that of the bootstrapping approach (average
F1: 0.292). Both approaches perform better than the co-occurrence
approach with 19,055 genes and 6516 drugs as input (precision of
0.015, recall of 1.000 and F1 of 0.030 at cutoff of 100%).
By examining the errors (false positives) for the dictionary-
based approach, we found that many of these errors are caused
by inclusion of non-PGx-speciﬁc genes in the input gene lexicon.
For example, we extracted 288 drug-AR pairs, 396 drug-VDR pairs
and 127 drug-EGFR pair since gene symbols ‘AR’, ‘VDR’ and ‘EGFR’
are included in the gene lexicon. Among the 4399 PGx drug–gene
pairs extracted from PharmGKB, there are 11 drug-EGFR pairs such
as cetuximab-EGFR and cisplatin-EGFR, 18 drug-VDR pairs such as
alendronate-VDR and calcium-VDR and 3 drug-AR pairs such asethanol-AR and paroxetine-AR. On the other hand, using the boot-
strapping approach (with seed warfain-CYP2C9), we extracted only
11 drug-EGFR pairs, 0 drug-AR pairs and 0 drug-VDR pairs since
PGx-speciﬁc drug–gene pairs such as warfarin-CYP2C9 often do
not appear together with non-PGx-speciﬁc drug–gene pairs such
as drug-AR or drug-VDR pairs.
One of the limitations inherent in this comparison is thatwe only
implemented the most primitive dictionary-based method: co-
occurrence ranked by frequency. More advanced implementation
will have better performance than that shown here. The take-home
message is that the bootstrapping approach by itselfmay not be suf-
ﬁcient as a standalone drug–gene relationship extraction method,
but it effectively removed many false positives. Its output is en-
riched with PGx-speciﬁc drug–gene pairs compared to the dictio-
nary-based co-occurrence method and can be used as input for
more sophisticated methods to further improve the performance.
3.6. Analyze the correlations between the extracted PGx-speciﬁc drug–
gene pairs and drug adverse events
A total of 100,049 drug adverse event pairs were downloaded
from SIDER. For the 996 drugs contained in these drug–gene pairs,
a total of 495,510 drug–drug combination pairs (order ignored) are
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pairs is 20.4. Among the 996 drugs, 557 of them were mapped to
the 2622 drug–gene pairs (extracted using seed warfarin-CYP2C9
after two iterations). A total of 154,846 drug–drug pairs are possi-
ble for these 557 drugs. The average number of shared adverse
events for these drug–drug pairs is 28.2. The number of shared side
effects increases to 37.4 for drug–drug pairs sharing at least one
gene (Fig. 4). The same is true for drug–gene pairs extracted using
other PGx-speciﬁc seeds (‘‘Caffeine_CYP1A2’’ and ‘‘FDA_PGx’’). The
number of shared adverse events increases from 28.2 to 41.7 as the
number of share PGx-speciﬁc genes increases from 0 to 5. The cor-
relation between drug–gene pairs extracted based on pure co-
occurrence (‘‘Cooc_All’’) and drug adverse event associations is less
signiﬁcant. The strong positive correlation between the extracted
PGx-speciﬁc drug–gene pairs and drug adverse event pairs demon-
strated that these pairs may have potential in computational ap-
proaches in studying drug adverse events for personalized
medicine.
4. Discussion
We developed a large-scale, semi-supervised relationship
algorithm to extract PGx-speciﬁc drug–gene pairs from 20 mil-
lion published MEDLINE abstracts. Starting with a few seeds,
our extraction algorithm achieved a precision of 0.219, a recall
of 0.368, and an F1 of 0.274 after two iterations, marking a sig-
niﬁcant improvement over methods using non-PGx-speciﬁc
seeds (precision: 0.011, recall: 0.018, and F1: 0.014) or no seeds
(precision: 0.015, recall: 1.000, and F1: 0.030). The ranking algo-
rithm effectively ranked PGx-speciﬁc pairs highly and further
signiﬁcantly improved the precision from 0.219 for all extracted
pairs to 0.561 for the highest ranked pairs. However, there are
several limitations to our study.
First of all, even though our algorithm has signiﬁcantly im-
proved precision over methods using non-PGx-speciﬁc seed or
without using any seed (0.219 vs. 0.015) and the ranking algo-
rithm was able to further rank PGx-speciﬁc drug–gene pairs
highly, the overall precision is still low. Starting from a PGx-spe-
ciﬁc seed, the algorithm implicitly classiﬁes sentences into PGx-
related or non-related. However, if n drugs and m genes co-occur
in a PGx-speciﬁc sentences, the algorithm will extraction all
n  m possible drug–gene pairs. The ranking algorithm then ranks
each of these n  m drug–gene pairs based on the ranking scores
of other co-occurring pairs. Both extraction and ranking algo-Fig. 4. Correlation between extracted PGx-speciﬁc drug–gene pairs (using different
seeds) with known drug adverse event associations.rithm are probabilistic and do not take into account of the syn-
tactic relationships between drug entities and gene entities in
sentences. Consider the following sentence: ‘‘Fifteen healthy sub-
jects were administered single oral doses of caffeine (CYP1A2),
warfarin (CYP2C9), omeprazole (CYP2C19), dextromethorphan
(CYP2D6), and midazolam (CYP3A)’’ (PMID 16638741). There
are ﬁve drugs and ﬁve genes in the sentence. Our algorithm will
extract total of 5  5 = 25 drug–gene pairs from this sentence. In
this case, manual curation, deep syntactic analysis, or prior
knowledge are necessary. Even though our algorithm cannot de-
cide the exact drug–gene correspondences in this case, it is able
to ﬁnd this PGx-related sentence out of millions of non-PGx-spe-
ciﬁc sentences in MEDLINE and ﬁltering out many non-PGx-spe-
ciﬁc drug–gene pairs. Currently, we are developing a semi-
automatic method to construct an accurate and comprehensive
PGx-speciﬁc drug–gene knowledge base from published litera-
ture. We will use the semi-supervised method to ﬁrst implicitly
classify MEDLINE sentences into PGx-related or non-related. We
will then manually extract drug–gene pairs from these classiﬁed
PGx-related sentences. The newly extracted drug–gene pairs will
immediately be fed into the extraction and ranking algorithm in
a positive feedback loop and newly ranked sentences and drug–
gene pairs will be presented to curators for conﬁrmation or
rejection. Both accepted and rejected pairs are used in the auto-
matic learning process.
Second, the precision and recall calculation of the algorithm
largely depend on the precision and recall of the gold standard.
As we discussed previously, the drug–gene pairs in PhamGKB are
limited in both precision and recall. The drug–gene pairs in
PharmGKB are largely PGx-speciﬁc and not biased to certain sets
of drugs or genes; therefore using them as gold standard to com-
pare different algorithms should give fair evaluation. However,
the precision and recall may not reﬂect the real measures of
the algorithms. We will need to manually create gold standard
datasets for MEDLINE-based drug–gene relationship extraction.
For example, for a given drug or gene, we can ﬁnd all the sen-
tences and abstracts wherein it appears. We can then extract
PGx-speciﬁc drug–gene pairs from these retrieved sentences
and abstracts to create MEDLINE-based PGx-speciﬁc drug–gene
relationship extraction gold standards.
Third, the entire drug–gene relationship extraction algorithm
starts with 19,055 human protein-coding genes, 6707 drugs, 20
million MEDLINE abstracts, and a few PGx-speciﬁc drug–gene pairs
as seeds. During the extraction and ranking process, many non-
PGx-speciﬁc MEDLINE sentences were automatically excluded.
However, if we can rank the 19,055 human protein-coding genes,
most of which are not PGx-related, according to their PGx speciﬁc-
ity, we can further improve the precision of the relationship extrac-
tion algorithm. We recently developed a gene-prioritizing
algorithm to rank all human genes according to their relevance
in drug metabolism [129]. In our future study, we will incorporate
the gene ranking score into the pair-ranking algorithm to further
improve the precision.
Fourth, we compared the performance of our drug–gene extrac-
tion algorithm to that of baseline method instead of state-of-art
approaches. The reason is that most of the state-of-art PGx-speciﬁc
drug–gene approaches used either PGx-speciﬁc gene lexicons as
input or limited set of PGx-related articles as the text corpus,
which already have much better baseline in terms of precision.
On the other hand, we started with all 19,055 human protein-cod-
ing genes, 6707 drugs, 20 million MEDLINE abstracts, and a few
PGx-speciﬁc drug–gene pairs as seeds. In order for algorithms to
be comparable to each other, the algorithms should take the same
inputs: gene lexicon, drug lexicon and text corpus. It will be inter-
esting to compare the overall performance when other algorithms
take the same inputs we used in this study.
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We developed a bootstrapping, semi-supervised learning ap-
proach to iteratively extract and rank drug–gene pairs according
to their relevance to drug pharmacogenomics. Starting with
19,055 human protein-coding genes, 6707 drugs, 20 million MED-
LINE abstracts, and a few PGx-speciﬁc drug–gene pairs as seeds,
the extraction algorithm achieved a precision of 0.219, a recall of
0.368, and an F1 of 0.274 after two iterations, which is a signiﬁcant
improvement over the results of using any seeds (precision: 0.015,
recall: 1.000, and F1: 0.030). The ranking algorithm effectively
ranked PGx-speciﬁc pairs highly and further improved the preci-
sion from 0.219 to 0.561. By comparing to a dictionary-based ap-
proach with PGx-speciﬁc gene lexicon as input, we showed that
the bootstrapping approach has better performance in terms of
precision and F1 (precision: 0.251 vs. 0.152, recall: 0.396 vs.
0.856 and F1: 0.292 vs. 0.254). To demonstrate the connection be-
tween drug metabolism and drug adverse events, we show that
drug–drug pairs sharing at least one PGx-speciﬁc gene also share
signiﬁcant more adverse events (28.2 for all pairs vs. 37.4 for pairs
sharing at least one PGx-speciﬁc gene). In the future, we will devel-
op automatic and semi-automatic methods to further improve
both precision and recall of the extracted drug–gene pairs and
use the extracted pairs in drug adverse event prediction.Acknowledgments
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